G Protein-Coupled Receptors in Cancer Progression

Dear Colleagues,

G protein-coupled receptors (GPCRs), the largest family of cell surface receptors, serve as critical regulators in a myriad of cellular processes. The dysregulation of GPCR signaling pathways has been implicated in fueling tumor growth, invasion, and metastasis, thus highlighting their potential as promising therapeutic targets for cancer treatment. Numerous mutations within GPCRs and heterotrimeric G proteins have been identified, yet the full functional significance of these mutations remains incompletely understood. Moreover, despite the fact that over 30% of currently available drugs target GPCRs, their application in cancer treatment remains limited, underscoring the underexplored potential of GPCRs in the context of cancer research. Therefore, there is a compelling need to delve deeper into the intricate mechanisms governing GPCR signaling in the context of cancer progression. Such endeavors hold immense promise for unveiling novel therapeutic avenues that can effectively combat the multifaceted challenges posed by this complex disease.

With this imperative in mind, we are pleased to extend an invitation to you to contribute to our upcoming Special Issue entitled "Novel Insights into GPCR Signaling in Cancer Development". This special edition aims to compile the latest breakthroughs and pivotal discoveries in both basic and translational research concerning the role of GPCR signaling in cancer development. We eagerly welcome original research articles and comprehensive reviews that explore various aspects of this complex landscape. Topics of interest include, but are not limited to, elucidating the functions and molecular mechanisms of GPCRs and G proteins, investigating their mutations in the context of cancer development, and exploring innovative therapeutic modalities such as small-molecule inhibitors tailored to target GPCR signaling pathways in cancer.

We eagerly anticipate the submission of your invaluable contributions to enrich this Special Issue with diverse perspectives and groundbreaking insights.

Dr. Songhai Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• GPCRs
• heterotrimeric G proteins
• signal transduction
• mutations
• cancer development